Registration
Description
Dr. Tehila Ben Moshe is the Co-Founder, CEO and Chairwoman of Biond Biologics, an innovative biotech company founded in 2016 and aims to discover and develop breakthrough therapies for the treatment of cancer.
Prior to that Dr. Ben-Moshe was the CEO and VP R&D of cCAM Biotherapeutics, a company that developed novel immunoncology biological drug for the treatment of solid tumors. cCAM biotherapeutics was fully acquired by Merck Sharp & Dohme (MSD) in July 2015. During her period at cCAM, Dr. Ben-Moshe showed strong management and leadership skills, including bringing an early stage company from inception to a successful proof of concept and clinical trials.
After cCAM Biotherapeutics acquisition, Dr. Ben-Moshe founded Biond Biologics together with the scientific team that worked with her at cCAM and additional professionals from the Israeli Biotech. She brought to the young company leadership, scientific excellence and high motivation to discover new therapies to high unmet medical needs, mainly to cancer.
Biond Biologics focus on developing innovative biological drugs for novel oncology targets by uncovering immunoregulatory pathways and by enabling the intracellular delivery of biologics. The company’s vision is to bring its innovative drugs to patients based on synergistic long-term collaborations with leading global companies.
Since its inception, Biond Biologics built a pipeline of novel drug candidates by translating high quality science and out-of-the-box innovative thinking into its breakthrough therapies to cancer. Biond Biologics is progressing its drug candidate into clinical trials and created value by generating synergistic partnerships with leading pharma companies in the field
Event
Tehila Ben Moshe
Organizer contact
Development Company for Israel (International) Ltd
Joe Ozer
Address : Lady Ruth House, Gabriel Mews, Crewys Road
NW2 2GD London
UNITED KINGDOM
Phone : 02039362712